1naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => OpenAccess
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
PT  - JOURNAL ARTICLE
AU  - Dodson, C.
AU  - Richards, T.J.
AU  - Smith, D.A.
AU  - Ramaiya, N.H.
TI  - Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists
AID  - 10.3174/ajnr.A6477
DP  - 2020 May 01
TA  - American Journal of Neuroradiology
PG  - 738--750
VI  - 41
IP  - 5
4099  - http://www.ajnr.org/content/41/5/738.short
4100  - http://www.ajnr.org/content/41/5/738.full
SO  - Am. J. Neuroradiol.2020 May 01; 41
AB  - SUMMARY: Treatment options for patients who develop brain metastases secondary to non-small-cell lung cancer have rapidly expanded in recent years. As a key adjunct to surgical and radiation therapy options, systemic therapies are now a critical component of the oncologic management of metastatic CNS disease in many patients with non-small-cell lung cancer. The aim of this review article was to provide a guide for radiologists, outlining the role of systemic therapies in metastatic non-small-cell lung cancer, with a focus on tyrosine kinase inhibitors. The critical role of the blood-brain barrier in the development of systemic therapies will be described. The final sections of this review will provide an overview of current imaging-based guidelines for therapy response. The utility of the Response Assessment in Neuro-Oncology criteria will be discussed, with a focus on how to use the response criteria in the assessment of patients treated with systemic and traditional therapies.ALKanaplastic lymphoma kinaseCTLA-4cytotoxic T-lymphocyte-associated protein 4EGFRepidermal growth factor receptorEML4echinoderm microtubule-associated protein-like 4ICIimmune checkpoint inhibitorNSCLCnon-small-cell lung cancerPD-1programmed cell death protein 1PFSprogression-free survivalPRESposterior reversible encephalopathy syndromeQALYquality-adjusted life yearsRANOResponse Assessment in Neuro-OncologyRECISTResponse Evaluation Criteria in Solid TumorsROS1C-ras oncogene 1SRSstereotactic radiosurgeryTKItyrosine kinase inhibitorWBRTwhole-brain radiation therapy